PRANTAL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PRANTAL (PRANTAL).
Prantal (diphemanil methylsulfate) is a quaternary ammonium anticholinergic agent that competitively inhibits muscarinic acetylcholine receptors (M1, M2, M3 subtypes), reducing gastrointestinal motility, gastric acid secretion, and bronchial secretions. It does not cross the blood-brain barrier.
| Metabolism | Metabolized primarily by ester hydrolysis (plasma and tissue esterases) with minimal hepatic cytochrome P450 involvement. Excreted unchanged in urine and bile. |
| Excretion | Primarily renal (50-70% unchanged) with minor biliary excretion; fecal elimination accounts for approximately 10-20%. |
| Half-life | Terminal elimination half-life is 4-6 hours; steady-state achieved within 24 hours in patients with normal renal function. |
| Protein binding | Approximately 25-35%, primarily to albumin. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is 30-60% due to first-pass metabolism. |
| Onset of Action | Oral: 30-60 minutes; intravenous: 2-5 minutes. |
| Duration of Action | 4-6 hours; may be prolonged in patients with hepatic impairment. |
50-100 mg orally 3-4 times daily; maximum 600 mg/day
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: 50 mg 3 times daily; GFR 10-29 mL/min: 50 mg twice daily; GFR <10 mL/min: 50 mg once daily |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 50% of normal dose; Child-Pugh C: avoid use |
| Pediatric use | 1-2 mg/kg/day orally divided every 6-8 hours; maximum 50 mg per dose |
| Geriatric use | Start at 25 mg 3 times daily; increase cautiously; monitor for anticholinergic effects |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PRANTAL (PRANTAL).
| Breastfeeding | Excreted in breast milk in trace amounts; M/P ratio not determined. Limited data suggest no adverse effects in nursing infants. Use with caution due to potential anticholinergic effects like dry mouth or constipation in the infant. |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: limited human data, animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: no known fetal adverse effects, but use only if clearly needed due to anticholinergic properties potentially causing neonatal tachycardia or meconium ileus. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to diphemanil; narrow-angle glaucoma; obstructive uropathy; gastrointestinal obstruction (e.g., pyloric stenosis, paralytic ileus); severe ulcerative colitis; toxic megacolon; myasthenia gravis (relative); concurrent use with other anticholinergics may exacerbate.
| Precautions | Risk of heat prostration in hot environments due to anhidrosis; caution in glaucoma, benign prostatic hyperplasia, myasthenia gravis, hyperthyroidism, coronary artery disease, and hiatal hernia with reflux esophagitis; may impair cognitive or motor function despite limited CNS penetration; monitor for anticholinergic toxicity. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure, heart rate, and urinary retention. Fetal monitoring: assess for tachycardia and meconium ileus if used near term. No specific monitoring during labor and delivery beyond standard. |
| Fertility Effects | No known negative effect on fertility based on animal studies. Anticholinergic effects may theoretically impact reproductive function due to altered secretions, but human data are lacking. |